Pacer Advisors Inc. Buys 172 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Pacer Advisors Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,972 shares of the medical research company’s stock after purchasing an additional 172 shares during the period. Pacer Advisors Inc.’s holdings in IQVIA were worth $3,335,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Capital Performance Advisors LLP purchased a new stake in IQVIA in the third quarter worth about $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the 3rd quarter valued at approximately $28,000. Avior Wealth Management LLC grew its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. raised its holdings in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after buying an additional 99 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on IQV. Stephens assumed coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. BTIG Research dropped their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target on the stock. Leerink Partners reiterated an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Robert W. Baird reduced their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Stock Up 1.7 %

Shares of IQV stock opened at $201.42 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company’s fifty day moving average price is $200.34 and its 200-day moving average price is $220.78. The company has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 2.14 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.